RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
about
Redox-directed cancer therapeutics: molecular mechanisms and opportunitiesMechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapyUsing large-scale genomics data to identify driver mutations in lung cancer: methods and challengesMechanisms of omega-3 polyunsaturated fatty acids in prostate cancer preventionEmerging roles of Nrf2 signal in non-small cell lung cancerHER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interactionComparative analysis of NRF2-responsive gene expression in AcPC-1 pancreatic cancer cell lineStress-activated cap'n'collar transcription factors in aging and human diseaseCACUL1/CAC1 Regulates the Antioxidant Response by Stabilizing Nrf2The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancerThe Keap1-Nrf2 system in cancers: stress response and anabolic metabolismMechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative diseaseInhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabineTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerRNA Interference and Cancer TherapyNrf2: friend or foe for chemoprevention?Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinomaA rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probeLoss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene.8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer.Suppression of radiation-induced migration of non-small cell lung cancer through inhibition of Nrf2-Notch AxisHigh levels of Nrf2 determine chemoresistance in type II endometrial cancerPERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damageAdaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1.pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis.Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases.Ionizing radiation activates the Nrf2 antioxidant response.NRF2 and cancer: the good, the bad and the importance of context.Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapyNrf2 expression in endometrial serous carcinomas and its precancers.Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cellsInvolvement of ERK-Nrf-2 signaling in ionizing radiation induced cell death in normal and tumor cells.Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.
P2860
Q24645584-89B52521-117F-457B-9D5A-DDB7A3C4AC04Q26751146-848FAA27-C155-475D-952E-24F4A391A856Q26800833-168DF7ED-4994-41D7-9B45-AB16811CAB51Q26830150-4C582439-8174-4C5C-BCE3-2DE621C696D9Q28078928-4434EE71-919A-428E-B9D4-CE193B82EE35Q28383407-7644CA14-FF4A-496C-9DAF-BE1B7A343B61Q28384407-1E1F7D6D-A444-42D0-BC37-5607766DFAAAQ28384783-162847A9-F34C-413A-A1F0-9E13F5AD667FQ28384997-4D3394DE-E1FC-4E49-A74A-A4FD836BA499Q28387975-0B0ABE76-F6CF-40C3-B369-14188A188ECEQ28392347-A1D65B66-5580-4E51-9CED-0DC0232449F0Q28394732-95AD8497-4C0D-49D2-AB90-2A16F2265F6BQ28396251-FC81BCAC-7ED3-4785-81D5-0ED9D2840B5FQ28396304-1F31C888-73DD-424F-9565-088B81B31946Q29392204-E27B89D8-CF10-4D98-9934-504F2F431C95Q33575690-1379C0F7-244C-4F39-BC1E-329E10937A3EQ33582954-7217EBE5-E5D6-499F-9251-FDE22EC7FFDEQ33633775-02648283-B690-4C09-BCB6-7D7045F24DF7Q33652512-FC96778F-D302-46F4-BA47-D1BB367B9668Q33657470-138EB8BC-897D-48AC-9C0C-F3CE735AC6F8Q33660069-C79DF556-C7C5-44E7-B06F-D8123C6FA18FQ33713310-BB2DC719-B254-4D6C-A298-898762E7D8EFQ33747354-5E4D9D4D-E4FA-466A-B5D4-F12DC9A3E718Q33829585-C654EC51-CA35-49F8-B412-2D84526D650AQ33959077-7A577626-9EFC-477D-844A-E817CA3896B3Q33977034-FC6AAE91-D076-4C73-920C-6AE36ABBA1C8Q34019923-A96E856B-23FA-491B-A392-A090B72FCC8CQ34059878-16AA35CB-A3DE-4140-BD2A-5D7B1A985128Q34062498-D527EA4A-C7A8-4D14-884C-8CA76B92DB06Q34146310-AC2699B2-31EC-4060-84B6-6547A0BEB164Q34204333-70C78D70-A8A9-4D1F-92DC-CD7C0D6BE414Q34252986-5FBF8F4E-9F7A-45D6-AA60-8CAC893B0D73Q34268193-ED3C0560-1D6E-42DB-9F40-88FBD132058FQ34289003-6B8843DF-DCE1-4B4B-8951-2709BB4861BAQ34348175-398EF7C1-2373-4346-B25D-949AC146AD19Q34467239-E4916886-15BE-4B9D-9F8B-396A39B09531Q34534013-F89F83BB-E838-498C-8936-EB32B7175736Q34637108-C8F5FC93-7278-4E91-8FD8-71CB1C373979Q34776063-9AED299E-46C6-41F9-9549-EF13EBAC373DQ34993085-E0F35B34-98CB-4A49-A92D-B99D08CCDC42
P2860
RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@ast
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@en
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@nl
type
label
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@ast
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@en
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@nl
prefLabel
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@ast
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@en
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@nl
P2093
P2860
P1433
P1476
RNAi-mediated silencing of nuc ...... ases efficacy of chemotherapy.
@en
P2093
Amanda Blackford
Anju Singh
Edward Gabrielson
Elena Feinstein
Hagit Ashush
Jonathan Coulter
Rajesh K Thimmulappa
Shyam Biswal
Srikanta K Rath
P2860
P304
P356
10.1158/0008-5472.CAN-08-1401
P407
P577
2008-10-01T00:00:00Z